The specificity of amylin for the diagnosis of pancreatic adenocarcinoma

International Journal of Gastrointestinal Cancer

Volumn 31, Issue 1-3, 2002, Pages 123-128

  Brand, Randall E ^a   Ding, Xian Zhong ^b   Young, Christine M ^c   Adrian, Thomas E ^b  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Amylin; Diagnosis; Pancreatic cancer; Tumor marker

Indexed keywords

AMYLIN; BIOLOGICAL MARKER; TUMOR MARKER;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; BILE DUCT OBSTRUCTION; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; GLUCOSE TOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

EID: 0036938058     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:31:1-3:123     Document Type: Article

References (16)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer Statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721-731.
3. Brand RE, Matamoros A. Imaging techniques in the evaluation of adenocarcinoma of the pancreas. Dig Dis 1998;16:242-252.
4. Schwarz SS, Zeidler A, Moossa AR, et al. A prospective study of glucose tolerance, insulin, C-peptide and glucagon responses in patients with pancreatic carcinoma. Dig Dis Sci 1978;23:1107-1114.
5. Permert J, Ihse I, Jorfeldt L, et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993;159:101-107.
6. Permert J, Larsson J, Westermark GT, et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Eng J Med 1994;330:313-318.
7. Bretherton-Watt D, Ghatei MA, Bloom SE, et al. Islet amyloid polypeptide-like immunoreactivity in human tissue and endocrine tumors. J Clin Endocrinol Metab 1993;76:1072-1074.
8. Butler PC, Chou J, Carter WB, et al. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 1990;39:752-756.
9. Sanke T, Hanabusa T, Nakano Y, et al. Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991;34:129-132.
10. Hartter E, Svoboda T, Ludvik B, et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin. Diabetologia 1991;34:52-54.
11. Eriksson J, Nakazato M, Miyazato M, et al. Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35:291-293.
12. Phillips AR, Abu-Zidan FM, Bonham MJ, et al. Amylin and severe acute pancreatitis. Pancreas 2000;20:105-106.
13. Chari S, Klee GG, Miller LJ, et al. Sensitivity and specificity of CA 19-9 and islet amyloid polypeptide (IAPP) for symptomatic pancreatic cancer (PC). Abstract for American Pancreatic Association Mtg 1998. Gastroenterology 2001;121:640-645.
14. Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma. Pancreas 1992;7:66-86.
15. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-355.
16. Kondo H, Sugano K, Fukayama N, et al. Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 1994;73:1589-1594.